Skip to content

Advertisement

Infection, immunity and cancer vaccines

Section edited by Christophe Nicot

This section focuses on all aspects of infectious agents associated with cancer and tumor immunology. Topics of interest include, but are not limited to, tumor immunity, immunotherapy, cancer vaccines, viral carcinogenesis and virus-host interactions.

Page 1 of 6
  1. Content type: Research article

    The hypercoagulable state associated with pancreatic adenocarcinoma (PDA) results in increased risk of venous thromboembolism, leading to substantial morbidity and mortality. Recently, neutrophil extracellular...

    Authors: Brian A. Boone, Pranav Murthy, Jennifer Miller-Ocuin, W. Reed Doerfler, Jarrod T. Ellis, Xiaoyan Liang, Mark A. Ross, Callen T. Wallace, Jason L. Sperry, Michael T. Lotze, Matthew D. Neal and Herbert J. Zeh III

    Citation: BMC Cancer 2018 18:678

    Published on:

  2. Content type: Research article

    RUNX1 overlapping RNA (RUNXOR) is a long non-coding RNA that has been indicated as a key regulator in the development of myeloid cells by targeting runt-related transcription factor 1 (RUNX1). Myeloid-derived ...

    Authors: Xinyu Tian, Jie Ma, Ting Wang, Jie Tian, Yu Zheng, Rongrong Peng, Yungang Wang, Yue Zhang, Lingxiang Mao, Huaxi Xu and Shengjun Wang

    Citation: BMC Cancer 2018 18:660

    Published on:

  3. Content type: Case report

    Immune checkpoint inhibitors are standard treatments for non-small cell lung cancer. Unique cases with paradoxical acceleration of the disease after immunotherapy have been reported. These have been described ...

    Authors: Taro Shinozaki, Eri Iwami, Shinnosuke Ikemura, Tatsu Matsuzaki, Takahiro Nakajima, Kazuhiko Hashimoto and Takeshi Terashima

    Citation: BMC Cancer 2018 18:620

    Published on:

  4. Content type: Research article

    Prognosis of pancreatic cancer is poor with a 5-year survival rate of only 7%. Although several new chemotherapy treatments have shown promising results, all patients will eventually progress, and we need to d...

    Authors: Yoshiki Hirooka, Hideki Kasuya, Takuya Ishikawa, Hiroki Kawashima, Eizaburo Ohno, Itzel B. Villalobos, Yoshinori Naoe, Toru Ichinose, Nobuto Koyama, Maki Tanaka, Yasuhiro Kodera and Hidemi Goto

    Citation: BMC Cancer 2018 18:596

    Published on:

  5. Content type: Debate

    Tumors develop multiple mechanisms of immune evasion as they progress, with some cancer types being inherently better at ‘hiding’ than others. With an increased understanding of tumor immune surveillance, immu...

    Authors: Joshua P. Bates, Roshanak Derakhshandeh, Laundette Jones and Tonya J. Webb

    Citation: BMC Cancer 2018 18:556

    Published on:

  6. Content type: Research article

    All women are potentially at risk of developing cervical cancer at some point in their life, yet it is avoidable cause of death among women in Sub- Saharan Africa with a world incidence of 530,000 every year. ...

    Authors: Hillary Mabeya, Sonia Menon, Steven Weyers, Violet Naanyu, Emily Mwaliko, Elijah Kirop, Omenge Orango, Heleen Vermandere and Davy Vanden Broeck

    Citation: BMC Cancer 2018 18:557

    Published on:

  7. Content type: Research article

    The prognostic effect of elevated systemic inflammatory markers, including neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR), remains controversial in cancer patients. This meta-analysis wa...

    Authors: Ying Zhu, Sanqin Zhou, Yang Liu, Lingyun Zhai and Xiwen Sun

    Citation: BMC Cancer 2018 18:443

    Published on:

  8. Content type: Technical advance

    Tumor neoantigens are drivers of cancer immunotherapy response; however, current prediction tools produce many candidates requiring further prioritization. Additional filtration criteria and population-level u...

    Authors: Mary A. Wood, Mayur Paralkar, Mihir P. Paralkar, Austin Nguyen, Adam J. Struck, Kyle Ellrott, Adam Margolin, Abhinav Nellore and Reid F. Thompson

    Citation: BMC Cancer 2018 18:414

    Published on:

  9. Content type: Research article

    We conducted a phase I/Ib, open-label, single-arm trial to assess the safety, tolerability and optimal scheduling regimen of OTSGC-A24 cancer vaccine in patients with advanced gastric cancer.

    Authors: Raghav Sundar, Sun Young Rha, Hiroki Yamaue, Masahiro Katsuda, Koji Kono, Hyo Song Kim, Chan Kim, Kousaku Mimura, Ley-Fang Kua and Wei Peng Yong

    Citation: BMC Cancer 2018 18:332

    Published on:

  10. Content type: Research article

    Innate lymphoid cells (ILC) are part of a heterogeneous family of haematopoietic effector cells which lack re-arranged antigen-specific receptors. They promote host defense and contribute to tissue and metabol...

    Authors: Maryam Salimi, Ruozheng Wang, Xuan Yao, Xi Li, Xiyan Wang, Yuhui Hu, Xumei Chang, Peiwen Fan, Tao Dong and Graham Ogg

    Citation: BMC Cancer 2018 18:341

    Published on:

  11. Content type: Research article

    The prevalence of high-risk human papillomavirus (HPV) DNA in cases of oral cavity squamous cell carcinoma (SCC) varies widely. The aim of this study is to investigate the frequency of high-risk HPV DNA in a l...

    Authors: Priscila Marinho de Abreu, Anna Clara Gregório Có, Pedro Leite Azevedo, Isabella Bittencourt do Valle, Karine Gadioli de Oliveira, Sônia Alves Gouvea, Melissa Freitas Cordeiro-Silva, Iúri Drummond Louro, José Roberto Vasconcelos de Podestá, Jeferson Lenzi, Agenor Sena, Elismauro Francisco Mendonça and Sandra Lúcia Ventorin von Zeidler

    Citation: BMC Cancer 2018 18:324

    Published on:

  12. Content type: Research article

    Gallbladder cancer (GBC), although infrequent in industrialized countries, has high incidence rates in certain world regions, being a leading cause of death among elderly Chilean women. Surgery is the only eff...

    Authors: Paula Fluxá, Daniel Rojas-Sepúlveda, María Alejandra Gleisner, Andrés Tittarelli, Pablo Villegas, Loreto Tapia, María Teresa Rivera, Mercedes Natalia López, Felipe Catán, Mario Uribe and Flavio Salazar-Onfray

    Citation: BMC Cancer 2018 18:243

    Published on:

  13. Content type: Study protocol

    There is now a renewed interest in cancer vaccines. Patients responding to immune checkpoint blockade usually bear tumors that are heavily infiltrated by T cells and express a high load of neoantigens, indicat...

    Authors: Sheeba K. Thomas, Soung-chul Cha, D. Lynne Smith, Kun Hwa Kim, Sapna R. Parshottam, Sheetal Rao, Michael Popescu, Vincent Y. Lee, Sattva S. Neelapu and Larry W. Kwak

    Citation: BMC Cancer 2018 18:187

    Published on:

  14. Content type: Research article

    Breast cancer is considered the most common cancer in women worldwide and is the leading cause of cancer mortality. Sequences similar to Mouse Mammary Tumor Virus (MMTV) were detected in human breast cancer in...

    Authors: Reem Al Dossary, Khaled R. Alkharsah and Haitham Kussaibi

    Citation: BMC Cancer 2018 18:170

    Published on:

  15. Content type: Research article

    Radiofrequency ablation (RFA) can not only effectively kill hepatocellular carcinoma (HCC) tumour cells but also release tumour antigens that can provoke an immune response. However, there is no consensus rega...

    Authors: Shunli Shen, Hong Peng, Ye Wang, Ming Xu, Manxia Lin, Xiaoyan Xie, Baogang Peng and Ming Kuang

    Citation: BMC Cancer 2018 18:117

    Published on:

  16. Content type: Research article

    The new nine-valent vaccine against human papillomavirus (HPV) includes the four HPV genotypes (6, 11, 16, and 18) that are targeted by the older quadrivalent HPV vaccine, plus five additional oncogenic types ...

    Authors: María Paz-Zulueta, Ledicia Álvarez-Paredes, Juan Carlos Rodríguez Díaz, Paula Parás-Bravo, Ma. Encarnación Andrada Becerra, José María Rodríguez Ingelmo, María Montserrat Ruiz García, Joaquín Portilla and Miguel Santibañez

    Citation: BMC Cancer 2018 18:112

    Published on:

  17. Content type: Research article

    Patients with highly mutated tumors, such as melanoma or smoking-related lung cancer, have higher rates of response to immune checkpoint blockade therapy, perhaps due to increased neoantigen expression. Many c...

    Authors: Timothy O’Donnell, Elizabeth L. Christie, Arun Ahuja, Jacqueline Buros, B. Arman Aksoy, David D. L. Bowtell, Alexandra Snyder and Jeff Hammerbacher

    Citation: BMC Cancer 2018 18:87

    Published on:

  18. Content type: Research article

    Programmed cell death ligand 1 (PD-L1) is a potential predictive biomarker of the response to anti-PD-L1/anti- programmed cell death 1 (PD-1) therapy in multiple cancers, including triple negative breast cance...

    Authors: Ming Li, Anqi Li, Shuling Zhou, Yan Xu, Yaoxing Xiao, Rui Bi and Wentao Yang

    Citation: BMC Cancer 2018 18:4

    Published on:

Page 1 of 6